期刊文献+

凝血因子Ⅶ提高脓毒症小鼠的宿主免疫力的实验研究

Coagulation factor Ⅶ enhances host immunity in septic mice
下载PDF
导出
摘要 目的探讨凝血因子Ⅶ提高脓毒症小鼠的宿主免疫力的价值。方法 40只健康雄性C57BL/6小鼠随机分为假手术组(n=8)、脓毒症组(n=16)、FⅦ组(n=16),脓毒症组与FⅦ组都采用三棱针穿刺法建立脓毒症模型,FⅦ组小鼠在术后第2天开始给予FⅦ静脉注射,持续应用10 d。观察与记录所有小鼠存活情况,检测凝血功能[凝血酶原时间(PT)、血小板(PLT)、活化部分凝血酶时间(APTT)]与巨噬细胞移动抑制因子(MIF)变化情况。结果假手术组小鼠都成活,脓毒症组建立模型后在2 d内死亡4例,FⅦ组死亡3例,脓毒症造模成功。造模成功后10 d,脓毒症组与FⅦ组小鼠的死亡率分别为50.0%和7.7%,FⅦ组显著低于脓毒症组(P<0.05)。FⅦ组小鼠存活小鼠的PT、APTT、PLT值与脓毒症组存活小鼠对比差异有统计学意义(P<0.05),与假手术组对比差异无统计学意义(P>0.05)。FⅦ组小鼠存活小鼠的血清MIF值显著低于脓毒症组(P<0.05),与假手术组对比差异无统计学意义(P>0.05)。脓毒症组肺泡间隔显著增宽,肺间质内可见大量炎性细胞浸润,FⅦ组较脓毒症组肺损伤程度减轻假手术组肺组织结构功能完整。结论 FⅦ能提高脓毒症小鼠的宿主免疫力,改善凝血功能紊乱,促进肺病理组织恢复正常,降低脓毒症的病死率。 Objective To explore the values of coagulation factor Ⅶ in improving host immunity in sepsis mice. Methods 40 healthy male C57BL/6 mice were randomly divided into sham operation group (n=8), sepsis group (n=16), FⅦ group (n=16), sepsis group and FⅦ group were treated with three prism puncture method to establish sepsis model. FⅦ mice were given FⅦ intravenous injection at the beginning of postoperative 2 d, and were lasted for 10 d. observed and recorded the survival of all mice, and detected the changes of coagulation function and MIF. Results The mice in the sham operation group were all survived, and there were 4 mice and 3 mice were died in the sepsis group and FⅦ group, and the sepsis model were successfully established. After postoperative 10d, the mortality rates of sepsis group and FⅦ group were 50% and 7.7% respectively, and those in FⅦ group were significantly lower than those in sepsis group ( P 〈0.05). The postoperative 10d of values of PT, APTT and PLT in the FⅦ mice were significantly different from those in the sepsis group ( P 〈0.05), and there were no significant difference compared between the sham group and the sham group ( P 〉0.05). The serum MIF value of the FⅦ group mice were significantly lower than that of the sepsis group ( P 〈0.05), and there were no significant difference compared with sham operation group ( P 〉0.05). The alveolar septum in the sepsis group were significantly widened, and there were large number of inflammatory cells were found in the interstitial lung, the lung injury in the FⅦ group were better than that of the sepsis group, and the lung tissue structure of the sham operation group were complete. Conclusion FⅦ can improve the host immunity of sepsis mice, improve the disorder of coagulation function, promote the recovery of lung pathological tissue and reduce the mortality of sepsis.
作者 王德元 祁秉民 鄂维建 谢海林 WANG De-yuan;QI Bing-min;E Wei-jian(Department of Clinical Lab, Tibetan Hospital of Qinghai, Xining Qinghai 810007, China;Department of Clinical Lab, Affiliated Hospital of Qinghai University, Xining Qinghai 810016, China.)
出处 《临床和实验医学杂志》 2018年第20期2133-2136,共4页 Journal of Clinical and Experimental Medicine
基金 青海省科学技术成果(编号:96301715)
关键词 小鼠 脓毒症 凝血因子Ⅶ 免疫功能 凝血功能 Mice Sepsis Coagulation factor Ⅶ Immune function Coagulation function
  • 相关文献

参考文献10

二级参考文献55

  • 1付登科,陈大志.重组人凝血因子Ⅶa在肝脏移植中的应用进展[J].国际移植与血液净化杂志,2006,4(5):29-31. 被引量:3
  • 2Furie B, Furie BC. The molecular basis of blood coagulation [J]. Cell, 1988, 53(4): 505-518.
  • 3Stenflo J, Stenberg Y, Muranyi A. Calcium-binding EGF-like modules in coagulation proteinases: function of the calcium ion in module interactions [J]. Biochim Biophys Aeta, 2000, 1477(1/2) : 51-63.
  • 4Pike AC, Brzozowski AM, Roberts SM, et al. Structure of human faetor Ⅷa and its implications for the triggering of blood coagulation [J]. Proc Natl Aead Sei U S A, 1999, 96(16) : 8925-8930.
  • 5Gerotziafas GT, Zervas K, Arzoglou P, et al. On the mecha- nism of action of recombinant activated factor administered to patients with severe thromboeytopenia and life-threatening haemorrhage: focus on prothrombin activation [J]. Br J Haematol, 2002, 117(3): 705-708.
  • 6Liebman HA, Chediak J, Fink KI , et al. Activated recombi- nant human coagulation factor Ⅶ (rFⅧa)therapy for abdomi- nal bleeding in patients with inhibitory antibodies to factor Ⅷ [J]. Am J Hematol, 2000, 63(3) : 109-113.
  • 7Yilmaz D, Karapinar B, Balkan C, et al. Single-center experi- ence., use of recombinant factor Ⅶa for actue life-threatening bleading in children without congenital hemorrhagic disorder [J]. Pediatr Hematol Oncol, 2008, 25(4) : 301-311.
  • 8Sdnchez MP, Nebreda JB, Gareia VC. Recombinant activated factor Ⅶ prevents bleeding during a surgical procedure in a patient with uncontrollable rectal hemorrhage [J]. Am J Gastroenterol, 2002, 97(5): 1266-1267.
  • 9Hyllner M, Houltz E, Jeppsson A. Recombinant activated factor Ⅶ in the management of life-threatening bleeding in cardiac surgery [J]. Eur J Cardiothorae Surg, 2005, 28(2): 254-258.
  • 10Talbot M, Tien HC. The use of recombinant factor Ⅶa in trauma patients [J]. J Am Acad Orthop Surg, 2009, 17(8): 477-481.

共引文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部